Renalytix Plc

AIM:RENX Stock Report

Market Cap: UK£34.8m

Renalytix Management

Management criteria checks 2/4

Renalytix's CEO is James McCullough, appointed in Mar 2018, has a tenure of 6.75 years. total yearly compensation is $780.11K, comprised of 65.3% salary and 34.7% bonuses, including company stock and options. directly owns 9.79% of the company’s shares, worth £3.40M. The average tenure of the management team and the board of directors is 3.7 years and 1.4 years respectively.

Key information

James McCullough

Chief executive officer

US$780.1k

Total compensation

CEO salary percentage65.3%
CEO tenure6.8yrs
CEO ownership9.8%
Management average tenure3.7yrs
Board average tenure1.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has James McCullough's remuneration changed compared to Renalytix's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$28m

Jun 30 2024US$780kUS$510k

-US$33m

Mar 31 2024n/an/a

-US$37m

Dec 31 2023n/an/a

-US$42m

Sep 30 2023n/an/a

-US$44m

Jun 30 2023US$1mUS$601k

-US$46m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022n/an/a

-US$42m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022US$636kUS$601k

-US$45m

Mar 31 2022n/an/a

-US$50m

Dec 31 2021n/an/a

-US$44m

Sep 30 2021n/an/a

-US$38m

Jun 30 2021US$1mUS$586k

-US$35m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020US$488kUS$470k

-US$10m

Mar 31 2020n/an/a

US$28m

Dec 31 2019n/an/a

-US$8m

Sep 30 2019n/an/a

-US$5m

Jun 30 2019US$216kUS$269k

-US$42m

Compensation vs Market: James's total compensation ($USD780.11K) is above average for companies of similar size in the UK market ($USD348.83K).

Compensation vs Earnings: James's compensation has been consistent with company performance over the past year.

CEO

James McCullough (56 yo)

6.8yrs

Tenure

US$780,110

Compensation

Mr. James R. McCullough served as Independent Non-Executive Director of LungLife AI, Inc. from July 08, 2021 to October 24, 2024. Mr. McCullough is CEO of Renalytix Plc.and served as Chairman Mr. McCulloug...

Leadership Team

NamePositionTenureCompensationOwnership
James McCullough
CEO & Director6.8yrsUS$780.11k9.79%
£ 3.4m
Fergus Fleming
CTO & Executive Director6.8yrsUS$425.70k0.18%
£ 62.4k
Michael Donovan
Chief Medical Officer6.8yrsUS$380.01k0%
£ 0
Julian Baines
Executive Chairmanless than a yearUS$14.89k0.56%
£ 194.1k
Howard Doran
Presidentless than a yearno data0.030%
£ 10.5k
Joel Jung
Chief Financial Officerless than a yearno data0.063%
£ 21.9k
Salim Hamir
Company Secretaryno datano datano data

3.7yrs

Average Tenure

61.5yo

Average Age

Experienced Management: RENX's management team is considered experienced (3.7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
James McCullough
CEO & Directorno dataUS$780.11k9.79%
£ 3.4m
Fergus Fleming
CTO & Executive Director6.8yrsUS$425.70k0.18%
£ 62.4k
Julian Baines
Executive Chairmanless than a yearUS$14.89k0.56%
£ 194.1k
Erik Lium
Independent Non-Executive Director6.1yrsno datano data
Christopher Mills
Independent Non-Executive Director6.8yrsno data4.4%
£ 1.5m
Stephen Brunton
Member of Clinical Advisory Board1.3yrsno datano data
Matthew Budoff
Member of Clinical Advisory Board1.3yrsno datano data
Ralph Defronzo
Member of Clinical Advisory Board1.3yrsno datano data
Barry Freedman
Member of Clinical Advisory Boardno datano datano data
Joseph Vassalotti
Member of Clinical Advisory Board5.3yrsno datano data
Catherine Coste
Independent Non-Executive Director1.5yrsUS$68.15k0.085%
£ 29.4k
Holly Mattix-Kramer
Member of Clinical Advisory Board1.3yrsno datano data

1.4yrs

Average Tenure

57.5yo

Average Age

Experienced Board: RENX's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 18:27
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Renalytix Plc is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anita DushyanthBerenberg
Mark MassaroBTIG
David WestenbergGuggenheim Securities, LLC